Evidence supporting the use of: Bacillus coagulans
For the health condition: Crohn's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bacillus coagulans is a spore-forming probiotic bacterium sometimes used as an adjunctive therapy in gastrointestinal disorders, including inflammatory bowel diseases (IBD) such as Crohn's Disease. The rationale for its use is based on its ability to survive gastric acidity, reach the intestines, and modulate gut microbiota composition. Some in vitro and animal studies have suggested that B. coagulans can inhibit pathogenic bacteria, promote anti-inflammatory cytokine production, and improve gut barrier function. Small-scale clinical trials have explored its benefits in irritable bowel syndrome (IBS) and ulcerative colitis, with some reports of symptom relief and improved quality of life. However, evidence specific to Crohn's Disease is limited. A handful of pilot studies and case reports suggest potential improvements in symptoms such as abdominal pain, bloating, and stool frequency, but these trials are generally underpowered, lack rigorous controls, or include mixed IBD populations. Systematic reviews and guidelines currently do not strongly endorse B. coagulans for Crohn's Disease due to insufficient high-quality evidence.

In summary, while there is some scientific rationale and preliminary data supporting probiotic use in IBD, the direct evidence for Bacillus coagulans in Crohn's Disease remains weak and inconclusive. Its use should be considered experimental, and more robust, large-scale, placebo-controlled trials are needed to clarify its efficacy and safety in this context.

More about bacillus coagulans
More about Crohn's Disease